ViroMed
ViroMed Co., Ltd. (ViroMed), a leading biopharmaceutical company focusing on the development of innovative medicine, was established in 1996 and is headquartered in Seoul, Korea with a US presence in Atlanta Area. ViroMed has been listed on the KOSDAQ stock exchange (084990) since 2005. ViroMed has assembled a diverse pipeline of novel biologics and Botanical therapeutics in the areas of cardiovascular disease, cancer and immune disorder, with eight projects in clinical stages in the US, Korea, and China. The company has established several key partnerships with Reyon Pharm. (Korea), PMG Pharm. (Korea) and Beijing Northland Biotech (China). The founder of ViroMed is Professor Sunyoung Kim of Seoul National University (SNU), who holds academic degrees from SNU, MIT, Harvard and Oxford, and also served as an assistant professor at Harvard Medical School and a postdoctoral fellow at MIT. Rallied under the leadership of Prof. Kim, experts from various fields have been united to achieve one goal – to cure the incurables.
